Quick Answer
DNA X, Inc. reported Net Income Loss of -$33.65 million for the year ending 2024.
- DNA X, Inc. showed a decrease of -37,286.7% in Net Income Loss from 2023 to 2024.
- This data is from DNA X, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
- XBRL data for this metric is available from 2018 to 2024 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.07 million | Q2 2018: -$123.0 thousand | Q3 2018: $2.13 million | Q1 2019: -$5.12 million | Q2 2019: -$5.60 million | Q3 2019: -$6.78 million | Q1 2020: -$9.96 million | Q2 2020: -$7.10 million | Q3 2020: -$6.46 million | Q1 2021: -$9.28 million | Q2 2021: -$6.69 million | Q3 2021: -$10.94 million | Q1 2022: -$7.21 million | Q2 2022: -$4.23 million | Q3 2022: -$1.61 million | Q1 2023: $227.0 thousand | Q2 2023: $509.0 thousand | Q3 2023: $527.0 thousand | Q1 2024: -$2.91 million | Q2 2024: -$6.62 million | Q3 2024: -$2.51 million | Q1 2025: $458.0 thousand | Q2 2025: -$7.48 million | Q3 2025: -$4.75 million.
- Over the full 7 years of available data (2018 to 2024), DNA X, Inc.'s Net Income Loss has declined by 2,734.9%.
- Historical annual values: Fiscal year 2024: -$33.65 million | Fiscal year 2023: -$90.0 thousand | Fiscal year 2022: -$14.09 million | Fiscal year 2021: -$38.63 million | Fiscal year 2020: -$29.93 million | Fiscal year 2019: -$25.83 million | Fiscal year 2018: $1.28 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: